Skip to main content

Table 3 Adverse events

From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

 

Tofacitinib (n = 161)

Baricitinib (n = 81)

P value

All Events, n (%)

32 (19.9)

17 (21.0)

0.866

Infection

20 (12.4)

11 (13.6)

0.840

Herpes zoster

9 (5.6)

4 (4.9)

 

Pneumonia

6 (3.7)

1 (1.2)

 

Upper respiratory infection

4 (2.5)

3 (3.7)

 

Callus infection

 

1 (1.2)

 

Cytomegalovirus infection

 

1 (1.2)

 

Fungus infection

1 (0.6)

  

Sepsis

 

1 (1.2)

 

Gastrointestinal disorder

6 (3.7)

2 (2.5)

0.720

Gastric ulcer

 

1 (1.2)

 

Nausea

4 (2.5)

1 (1.2)

 

Diarrhea

2 (1.2)

  

Neoplasm

3 (1.9)

1 (1.2)

> 0.999

Breast cancer

 

1 (1.2)

 

Colon cancer

1 (0.6)

  

Skin cancer

1 (0.6)

  

Lung cancer

1 (0.6)

  

Others

3 (1.9)

3 (3.7)

0.405

Hair loss

1 (0.6)

  

Vertigo

1 (0.6)

1 (1.2)

 

Headache

 

1 (1.2)

 

Interstitial pneumonia

1 (0.6)

  

Elevation of creatine kinase

 

1 (1.2)

Â